+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Brain Cancer Drugs Market by Indication (Glioblastoma Multiforme, Meningioma, Metastatic Brain Tumors), Drug Class (Chemotherapy, Immunotherapy, Supportive Therapy), Route Of Administration, End User, Distribution Channel - Global Forecast 2025-2030- Product Image
Brain Cancer Drugs Market by Indication (Glioblastoma Multiforme, Meningioma, Metastatic Brain Tumors), Drug Class (Chemotherapy, Immunotherapy, Supportive Therapy), Route Of Administration, End User, Distribution Channel - Global Forecast 2025-2030- Product Image
Sale

Brain Cancer Drugs Market by Indication (Glioblastoma Multiforme, Meningioma, Metastatic Brain Tumors), Drug Class (Chemotherapy, Immunotherapy, Supportive Therapy), Route Of Administration, End User, Distribution Channel - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 193 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6011104
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The brain cancer drugs market is undergoing a rapid transformation, shaped by emerging therapeutic innovations, precision medicine, and evolving global regulations. Strategic adaptation is imperative for organizations seeking resilience and growth within this competitive sector.

Market Snapshot: Brain Cancer Drugs Market Growth and Trends

The brain cancer drugs market expanded from USD 2.18 billion in 2024 to USD 2.34 billion in 2025, and continues to grow at a CAGR of 7.45% to reach USD 3.36 billion by 2030. This market is propelled by fast-paced innovation in therapeutics, increased investment in biomarker-driven drug development, and strategic industry partnerships. Companies operating in this space are leveraging regulatory advancements and new care models to drive adoption and respond to rising global demand for more effective cancer treatment options.

Scope & Segmentation: Detailed Market Coverage

This research investigates a comprehensive array of segments and geographic regions to deliver actionable intelligence for industry stakeholders.

  • Indication Types: Glioblastoma multiforme, meningioma, metastatic brain tumors, pituitary tumors.
  • Drug Classes: Chemotherapy (including alkylating agents, antimetabolites, plant alkaloids); Immunotherapy (cancer vaccines, CAR-T therapy, checkpoint inhibitors); Supportive therapy (anti-emetics, growth factors); Targeted therapy (monoclonal antibodies, tyrosine kinase inhibitors).
  • Routes of Administration: Intrathecal, intravenous, oral.
  • End Users: Clinics, home healthcare, hospitals.
  • Distribution Channels: Hospital pharmacies, online pharmacies, retail pharmacies.
  • Regions: Americas (including United States, Canada, Mexico, Brazil, Argentina); Europe, Middle East & Africa (including United Kingdom, Germany, France, Russia, and additional markets); Asia-Pacific (including China, India, Japan, Australia, South Korea, and key regional economies).
  • Companies Profiled: F. Hoffmann-La Roche Ltd, Merck & Co., Inc., Bristol-Myers Squibb Company, Novartis AG, Pfizer Inc., Johnson & Johnson, Bayer Aktiengesellschaft, AbbVie Inc., Teva Pharmaceutical Industries Ltd, Amgen Inc.

Key Takeaways: Strategic Insights and Market Drivers

  • Precision medicine and immuno-oncology advancements are redefining brain cancer treatment standards, making therapies more patient-centric and adaptive.
  • Molecular profiling and biomarker-led strategies allow for personalized therapeutic approaches, directly influencing clinical outcomes and setting new expectations for care quality.
  • Integration of innovative administration methods, such as intrathecal and oral regimens, enhances patient adherence and broadens care accessibility across diverse healthcare settings.
  • Regional market requirements are shaped by unique regulatory processes and varying levels of digital health adoption, influencing launch strategies and patient access.
  • Strategic alliances among industry leaders, academic centers, and contract research organizations accelerate clinical development and maximize innovation pipelines.

Tariff Impact: Adjustments and Global Supply Chain Strategies

The 2025 US tariff modifications have complicated the global procurement landscape for brain cancer drugs. Elevated costs for imported active pharmaceutical ingredients have prompted manufacturers to diversify supply chains and pursue new manufacturing partnerships in low-tariff regions. These adjustments have ensured ongoing production but have also introduced logistical challenges for clinical trials and distribution, compelling protocol teams to develop contingency plans to safeguard delivery timelines and patient safety. The downstream effect on reimbursement frameworks and healthcare provider negotiations is prompting market stakeholders to share best practices and reinforce supply resilience.

Methodology & Data Sources

Research draws from primary interviews with neuro-oncologists, regulatory specialists, and clinical trial investigators, combined with secondary review of peer-reviewed literature, regulatory data, and clinical trial registries. Quantitative analysis leverages robust segmentation and statistical validation to produce reliable, actionable market intelligence.

Why This Report Matters for Decision-Makers

  • Gain competitive advantage by aligning commercial strategies with the latest regulatory innovations, technology advances, and patient-focused care models.
  • Leverage actionable segmentation data to identify market opportunities, guide strategic investments, and optimize value chains across global regions.

Conclusion

As the brain cancer drugs market evolves, adaptive and insight-driven strategies are essential for organizations aiming to improve patient outcomes and build long-term industry leadership. This report empowers stakeholders with the intelligence needed to navigate complexity and drive innovation in neuro-oncology.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Integration of next-generation sequencing biomarkers in personalized glioma therapy selection
5.2. Rising adoption of convection-enhanced delivery systems for localized brain tumor treatments
5.3. Development of blood-brain barrier-penetrating small molecule inhibitors for recurrent glioblastoma
5.4. Clinical advancement of oncolytic virus therapies combined with immune checkpoint inhibitors in brain cancer
5.5. Investment surge in bispecific antibody constructs targeting multiple glioma antigens for improved outcomes
5.6. Deployment of artificial intelligence algorithms to optimize radiotherapy planning and monitoring in brain tumors
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Brain Cancer Drugs Market, by Indication
8.1. Introduction
8.2. Glioblastoma Multiforme
8.3. Meningioma
8.4. Metastatic Brain Tumors
8.5. Pituitary Tumors
9. Brain Cancer Drugs Market, by Drug Class
9.1. Introduction
9.2. Chemotherapy
9.2.1. Alkylating Agents
9.2.2. Antimetabolites
9.2.3. Plant Alkaloids
9.3. Immunotherapy
9.3.1. Cancer Vaccines
9.3.2. CAR-T Therapy
9.3.3. Checkpoint Inhibitors
9.4. Supportive Therapy
9.4.1. Anti-Emetics
9.4.2. Growth Factors
9.5. Targeted Therapy
9.5.1. Monoclonal Antibodies
9.5.2. Tyrosine Kinase Inhibitors
10. Brain Cancer Drugs Market, by Route Of Administration
10.1. Introduction
10.2. Intrathecal
10.3. Intravenous
10.4. Oral
11. Brain Cancer Drugs Market, by End User
11.1. Introduction
11.2. Clinics
11.3. Home Healthcare
11.4. Hospitals
12. Brain Cancer Drugs Market, by Distribution Channel
12.1. Introduction
12.2. Hospital Pharmacies
12.3. Online Pharmacies
12.4. Retail Pharmacies
13. Americas Brain Cancer Drugs Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Brain Cancer Drugs Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Brain Cancer Drugs Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. F. Hoffmann-La Roche Ltd
16.3.2. Merck & Co., Inc.
16.3.3. Bristol-Myers Squibb Company
16.3.4. Novartis AG
16.3.5. Pfizer Inc.
16.3.6. Johnson & Johnson
16.3.7. Bayer Aktiengesellschaft
16.3.8. AbbVie Inc.
16.3.9. Teva Pharmaceutical Industries Ltd
16.3.10. Amgen Inc.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. BRAIN CANCER DRUGS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 6. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. BRAIN CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. BRAIN CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. BRAIN CANCER DRUGS MARKET: RESEARCHAI
FIGURE 26. BRAIN CANCER DRUGS MARKET: RESEARCHSTATISTICS
FIGURE 27. BRAIN CANCER DRUGS MARKET: RESEARCHCONTACTS
FIGURE 28. BRAIN CANCER DRUGS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. BRAIN CANCER DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY GLIOBLASTOMA MULTIFORME, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY GLIOBLASTOMA MULTIFORME, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY MENINGIOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY MENINGIOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY METASTATIC BRAIN TUMORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY METASTATIC BRAIN TUMORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY PITUITARY TUMORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY PITUITARY TUMORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ANTIMETABOLITES, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ANTIMETABOLITES, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY PLANT ALKALOIDS, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY PLANT ALKALOIDS, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CANCER VACCINES, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CANCER VACCINES, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CAR-T THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CAR-T THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ANTI-EMETICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ANTI-EMETICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY GROWTH FACTORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY GROWTH FACTORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY INTRATHECAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY INTRATHECAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 82. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 83. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 84. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 85. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 86. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 87. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 88. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 89. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2024 (USD MILLION)
TABLE 90. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2025-2030 (USD MILLION)
TABLE 91. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 92. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 93. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 94. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 95. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 96. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 97. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 98. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 99. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 100. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 101. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 102. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 103. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 104. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 105. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 106. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 107. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 108. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 109. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2024 (USD MILLION)
TABLE 110. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2025-2030 (USD MILLION)
TABLE 111. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 112. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 113. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 114. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 115. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 116. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 117. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 118. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 119. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 120. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 121. CANADA BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 122. CANADA BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 123. CANADA BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 124. CANADA BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 125. CANADA BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 126. CANADA BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 127. CANADA BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 128. CANADA BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 129. CANADA BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2024 (USD MILLION)
TABLE 130. CANADA BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2025-2030 (USD MILLION)
TABLE 131. CANADA BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 132. CANADA BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 133. CANADA BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 134. CANADA BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 135. CANADA BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 136. CANADA BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 137. CANADA BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 138. CANADA BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 139. MEXICO BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 140. MEXICO BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 141. MEXICO BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 142. MEXICO BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 143. MEXICO BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 144. MEXICO BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 145. MEXICO BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 146. MEXICO BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 147. MEXICO BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2024 (USD MILLION)
TABLE 148. MEXICO BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2025-2030 (USD MILLION)
TABLE 149. MEXICO BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 150. MEXICO BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 151. MEXICO BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 152. MEXICO BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 153. MEXICO BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 154. MEXICO BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 155. MEXICO BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 156. MEXICO BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 157. BRAZIL BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 158. BRAZIL BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 159. BRAZIL BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 160. BRAZIL BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 161. BRAZIL BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 162. BRAZIL BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 163. BRAZIL BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 164. BRAZIL BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 165. BRAZIL BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2024 (USD MILLION)
TABLE 166. BRAZIL BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2025-2030 (USD MILLION)
TABLE 167. BRAZIL BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 168. BRAZIL BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 169. BRAZIL BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 170. BRAZIL BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 171. BRAZIL BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 172. BRAZIL BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 173. BRAZIL BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 174. BRAZIL BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 175. ARGENTINA BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 176. ARGENTINA BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 177. ARGENTINA BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 178. ARGENTINA BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 179. ARGENTINA BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 180. ARGENTINA BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 181. ARGENTINA BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 182. ARGENTINA BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 183. ARGENTINA BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2024 (USD MILLION)
TABLE 184. ARGENTINA BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2025-2030 (USD MILLION)
TABLE 185. ARGENTINA BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 186. ARGENTINA BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 187. ARGENTINA BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 188. ARGENTINA BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 189. ARGENTINA BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 190. ARGENTINA BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 191. ARGENTINA BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 192. ARGENTINA BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 193. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 194. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 195. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 196. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 197. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 198. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 199. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 200. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 201. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2024 (USD MILLION)
TABLE 202. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2025-2030 (USD MILLION)
TABLE 203. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 204. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 205. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 206. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 207. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 208. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 209. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 210. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 211. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 212. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 213. UNITED KINGDOM BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 214. UNITED KINGDOM BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 215. UNITED KINGDOM BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 216. UNITED KINGDOM BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 217. UNITED KINGDOM BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 218. UNITED KINGDOM BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 219. UNITED KINGDOM BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 220. UNITED KINGDOM BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 221. UNITED KINGDOM BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2024 (USD MILLION)
TABLE 222. UNITED KINGDOM BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2025-2030 (USD MILLION)
TABLE 223. UNITED KINGDOM BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 224. UNITED KINGDOM BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 225. UNITED KINGDOM BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 226. UNITED KINGDOM BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 227. UNITED KINGDOM BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 228. UNITED KINGDOM BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 229. UNITED KINGDOM BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 230. UNITED KINGDOM BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 231. GERMANY BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 232. GERMANY BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 233. GERMANY BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 234. GERMANY BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 235. GERMANY BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 236. GERMANY BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 237. GERMANY BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 238. GERMANY BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 239. GERMANY BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2024 (USD MILLION)
TABLE 240. GERMANY BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2025-2030 (USD MILLION)
TABLE 241. GERMANY BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 242. GERMANY BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 243. GERMANY BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 244. GERMANY BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 245. GERMANY BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 246. GERMANY BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 247. GERMANY BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 248. GERMANY BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 249. FRANCE BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 250. FRANCE BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 251. FRANCE BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 252. FRANCE BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 253. FRANCE BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 254. FRANCE BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 255. FRANCE BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 256. FRANCE BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 257. FRANCE BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2024 (USD MILLION)
TABLE 258. FRANCE BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2025-2030 (USD MILLION)
TABLE 259. FRANCE BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 260. FRANCE BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 261. FRANCE BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 262. FRANCE BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 263. FRANCE BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 264. FRANCE BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 265. FRANCE BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 266. FRANCE BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 267. RUSSIA BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 268. RUSSIA BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 269. RUSSIA BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 270. RUSSIA BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 271. RUSSIA BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 272. RUSSIA BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 273. RUSSIA BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 274. RUSSIA BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 275. RUSSIA BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2024 (USD MILLION)
TABLE 276. RUSSIA BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2025-2030 (USD MILLION)
TABLE 277. RUSSIA BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 278. RUSSIA BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 279. RUSSIA BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 280. RUSSIA BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 281. RUSSIA BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 282. RUSSIA BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 283. RUSSIA BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 284. RUSSIA BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 285. ITALY BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 286. ITALY BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 287. ITALY BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 288. ITALY BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 289. ITALY BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 290. ITALY BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 291. ITALY BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 292. ITALY BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 293. ITALY BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2024 (USD MILLION)
TABLE 294. ITALY BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2025-2030 (USD MILLION)
TABLE 295. ITALY BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 296. ITALY BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 297. ITALY BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 298. ITALY BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 299. ITALY BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 300. ITALY BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 301. ITALY BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 302. ITALY BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 303. SPAIN BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 304. SPAIN BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 305. SPAIN BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 306. SPAIN BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 307. SPAIN BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 308. SPAIN BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 309. SPAIN BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 310. SPAIN BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 311. SPAIN BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2024 (USD MILLION)
TABLE 312. SPAIN BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2025-2030 (USD MILLION)
TABLE 313. SPAIN BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 314. SPAIN BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 315. SPAIN BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 316. SPAIN BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 317. SPAIN BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 318. SPAIN BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 319. SPAIN BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 320. SPAIN BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 321. UNITED ARAB EMIRATES BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 322. UNITED ARAB EMIRATES BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 323. UNITED ARAB EMIRATES BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 324. UNITED ARAB EMIRATES BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 325. UNITED ARAB EMIRATES BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 326. UNITED ARAB EMIRATES BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 327. UNITED ARAB EMIRATES BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 328. UNITED ARAB EMIRATES BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 329. UNITED ARAB EMIRATES BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2024 (USD MILLION)
TABLE 330. UNITED ARAB EMIRATES BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2025-2030 (USD MILLION)
TABLE 331. UNITED ARAB EMIRATES BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 332. UNITED ARAB EMIRATES BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 333. UNITED ARAB EMIRATES BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 334. UNITED ARAB EMIRATES BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 335. UNITED ARAB EMIRATES BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 336. UNITED ARAB EMIRATES BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 337. UNITED

Samples

Loading
LOADING...

Companies Mentioned

  • F. Hoffmann-La Roche Ltd
  • Merck & Co., Inc.
  • Bristol-Myers Squibb Company
  • Novartis AG
  • Pfizer Inc.
  • Johnson & Johnson
  • Bayer Aktiengesellschaft
  • AbbVie Inc.
  • Teva Pharmaceutical Industries Ltd
  • Amgen Inc.

Table Information

Report AttributeDetails
No. of Pages193
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 2.34 Billion
Forecasted Market Value ( USD ) by 2030 $ 3.36 Billion
Compound Annual Growth Rate7.4%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Pediatric Brain Tumors Drug Pipeline Analysis Report 2025 - Product Image

Pediatric Brain Tumors Drug Pipeline Analysis Report 2025

  • Drug Pipelines
  • 200 Pages
  • Global
From
Brain Tumor Drugs Market Report 2025 - Product Image

Brain Tumor Drugs Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Brain Tumor Therapeutics Market by Product Type (Devices, Pharmaceutical), Therapeutic Approach (Chemotherapy, Immunotherapy, Radiotherapy), Tumor Type, End User, Distribution Channel - Global Forecast 2025-2030 - Product Image

Brain Tumor Therapeutics Market by Product Type (Devices, Pharmaceutical), Therapeutic Approach (Chemotherapy, Immunotherapy, Radiotherapy), Tumor Type, End User, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 182 Pages
  • Global
From
Brain Tumor Diagnosis & Therapeutics Market by Therapeutic Modality, Imaging Technology, End User, Tumor Type, Tumor Grade, Patient Age Group - Global Forecast 2025-2030 - Product Image

Brain Tumor Diagnosis & Therapeutics Market by Therapeutic Modality, Imaging Technology, End User, Tumor Type, Tumor Grade, Patient Age Group - Global Forecast 2025-2030

  • Report
  • 183 Pages
  • Global
From
Brain Tumor Diagnosis and Treatment - Global Strategic Business Report - Product Image

Brain Tumor Diagnosis and Treatment - Global Strategic Business Report

  • Report
  • 173 Pages
  • Global
From

About the Brain Cancer Drugs Market

The Brain Cancer Drugs market is a segment of the pharmaceutical industry that focuses on the development and sale of drugs used to treat brain cancer. Brain cancer is a type of cancer that affects the cells of the brain and can be caused by a variety of factors, including genetics, environmental exposure, and lifestyle. Brain cancer drugs are used to treat the symptoms of brain cancer, such as headaches, seizures, and nausea, as well as to slow the progression of the disease. Brain cancer drugs are typically divided into two categories: chemotherapy and targeted therapy. Chemotherapy drugs are used to kill cancer cells, while targeted therapy drugs are designed to target specific cancer cells and stop them from growing. Both types of drugs are used in combination to treat brain cancer. Some of the major companies in the Brain Cancer Drugs market include Bristol-Myers Squibb, Merck, Pfizer, Novartis, and Roche. These companies are involved in the development and sale of drugs used to treat brain cancer, as well as in the research and development of new treatments. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.